The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials

HJ de Koning; ED Crawford; V Nelen; M Kwiatkowski; M Zappa; M Luján; A Villers; TM de Carvalho; EJ Feuer; A Tsodikov; AB Mariotto; R Gulati; EAM Heijnsdijk; R Etzioni; SM Moss; J Hugosson; PF Pinsky; CD Berg; A Auvinen; GL Andriole; MJ Roobol

doi:10.1002/cncr.31178

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials

HJ de Koning, ED Crawford, V Nelen, M Kwiatkowski, M Zappa, M Luján, A Villers, TM de Carvalho, EJ Feuer, A Tsodikov, AB Mariotto, R Gulati, EAM Heijnsdijk, R Etzioni, SM Moss, J Hugosson, PF Pinsky, CD Berg, A Auvinen, GL AndrioleMJ Roobol

Research output: Contribution to journal › Article › Scientific › peer-review

56 Citations (Scopus)

Original language	English
Journal	Cancer
DOIs	https://doi.org/10.1002/cncr.31178
Publication status	Published - 2017
Publication type	A1 Journal article-refereed

Keywords

modeling
mortality reduction
prostate cancer
prostate-specific antigen (PSA) screening

Publication forum classification

Publication forum level 2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cncr.31178

Cite this

de Koning, HJ., Crawford, ED., Nelen, V., Kwiatkowski, M., Zappa, M., Luján, M., Villers, A., de Carvalho, TM., Feuer, EJ., Tsodikov, A., Mariotto, AB., Gulati, R., Heijnsdijk, EAM., Etzioni, R., Moss, SM., Hugosson, J., Pinsky, PF., Berg, CD., Auvinen, A., ... Roobol, MJ. (2017). The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer. https://doi.org/10.1002/cncr.31178

@article{de4fcd43ed2c40a6a3415f8113cc59fd,

title = "The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials",

keywords = "modeling, mortality reduction, prostate cancer, prostate-specific antigen (PSA) screening, modeling, mortality reduction, prostate cancer, prostate-specific antigen (PSA) screening",

author = "{de Koning}, HJ and ED Crawford and V Nelen and M Kwiatkowski and M Zappa and M Luj{\'a}n and A Villers and {de Carvalho}, TM and EJ Feuer and A Tsodikov and AB Mariotto and R Gulati and EAM Heijnsdijk and R Etzioni and SM Moss and J Hugosson and PF Pinsky and CD Berg and A Auvinen and GL Andriole and MJ Roobol",

year = "2017",

doi = "10.1002/cncr.31178",

language = "English",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

}

de Koning, HJ, Crawford, ED, Nelen, V, Kwiatkowski, M, Zappa, M, Luján, M, Villers, A, de Carvalho, TM, Feuer, EJ, Tsodikov, A, Mariotto, AB, Gulati, R, Heijnsdijk, EAM, Etzioni, R, Moss, SM, Hugosson, J, Pinsky, PF, Berg, CD, Auvinen, A, Andriole, GL & Roobol, MJ 2017, 'The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials', Cancer. https://doi.org/10.1002/cncr.31178

TY - JOUR

T1 - The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials

AU - de Koning, HJ

AU - Crawford, ED

AU - Nelen, V

AU - Kwiatkowski, M

AU - Zappa, M

AU - Luján, M

AU - Villers, A

AU - de Carvalho, TM

AU - Feuer, EJ

AU - Tsodikov, A

AU - Mariotto, AB

AU - Gulati, R

AU - Heijnsdijk, EAM

AU - Etzioni, R

AU - Moss, SM

AU - Hugosson, J

AU - Pinsky, PF

AU - Berg, CD

AU - Auvinen, A

AU - Andriole, GL

AU - Roobol, MJ

PY - 2017

Y1 - 2017

KW - modeling

KW - mortality reduction

KW - prostate cancer

KW - prostate-specific antigen (PSA) screening

KW - modeling

KW - mortality reduction

KW - prostate cancer

KW - prostate-specific antigen (PSA) screening

U2 - 10.1002/cncr.31178

DO - 10.1002/cncr.31178

M3 - Article

SN - 0008-543X

JO - Cancer

JF - Cancer

ER -